R&D | January 16, 2026
Redesigned brain receptor drugs show promise for depression
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Subscribe To Our Newsletter & Stay Updated
